Last reviewed · How we verify

Vonoprazan+tetracycline+furazolidone 14 days

Xijing Hospital of Digestive Diseases · FDA-approved active Small molecule

Vonoprazan+tetracycline+furazolidone 14 days is a H. pylori eradication therapy (triple therapy) Small molecule drug developed by Xijing Hospital of Digestive Diseases. It is currently FDA-approved for Helicobacter pylori infection eradication.

This triple-drug combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan), inhibiting bacterial protein synthesis (tetracycline), and providing additional antimicrobial activity (furazolidone).

This triple-drug combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan), inhibiting bacterial protein synthesis (tetracycline), and providing additional antimicrobial activity (furazolidone). Used for Helicobacter pylori infection eradication.

At a glance

Generic nameVonoprazan+tetracycline+furazolidone 14 days
SponsorXijing Hospital of Digestive Diseases
Drug classH. pylori eradication therapy (triple therapy)
ModalitySmall molecule
Therapeutic areaGastroenterology / Infectious Disease
PhaseFDA-approved

Mechanism of action

Vonoprazan is a potassium-competitive acid blocker that raises gastric pH to optimize antibiotic efficacy. Tetracycline is a broad-spectrum antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Furazolidone is a nitrofuran antimicrobial agent that generates reactive oxygen species and damages bacterial DNA. Together, this regimen achieves high H. pylori eradication rates over 14 days.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Vonoprazan+tetracycline+furazolidone 14 days

What is Vonoprazan+tetracycline+furazolidone 14 days?

Vonoprazan+tetracycline+furazolidone 14 days is a H. pylori eradication therapy (triple therapy) drug developed by Xijing Hospital of Digestive Diseases, indicated for Helicobacter pylori infection eradication.

How does Vonoprazan+tetracycline+furazolidone 14 days work?

This triple-drug combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan), inhibiting bacterial protein synthesis (tetracycline), and providing additional antimicrobial activity (furazolidone).

What is Vonoprazan+tetracycline+furazolidone 14 days used for?

Vonoprazan+tetracycline+furazolidone 14 days is indicated for Helicobacter pylori infection eradication.

Who makes Vonoprazan+tetracycline+furazolidone 14 days?

Vonoprazan+tetracycline+furazolidone 14 days is developed and marketed by Xijing Hospital of Digestive Diseases (see full Xijing Hospital of Digestive Diseases pipeline at /company/xijing-hospital-of-digestive-diseases).

What drug class is Vonoprazan+tetracycline+furazolidone 14 days in?

Vonoprazan+tetracycline+furazolidone 14 days belongs to the H. pylori eradication therapy (triple therapy) class. See all H. pylori eradication therapy (triple therapy) drugs at /class/h-pylori-eradication-therapy-triple-therapy.

What development phase is Vonoprazan+tetracycline+furazolidone 14 days in?

Vonoprazan+tetracycline+furazolidone 14 days is FDA-approved (marketed).

What are the side effects of Vonoprazan+tetracycline+furazolidone 14 days?

Common side effects of Vonoprazan+tetracycline+furazolidone 14 days include Nausea, Diarrhea, Abdominal discomfort, Headache, Photosensitivity (tetracycline-related).

Related